GlassScriptPhysician profile
Elke K Friedman
NPI 1629073473
$23,318.30
in general payments reported to CMS, 2019-2025
60 companies · $4,093 in 2025
The $4,093 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,000 · 2020: $1,332 · 2021: $4,998 · 2022: $658 · 2023: $1,639 · 2024: $2,596 · 2025: $4,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,563 · Consulting Fee: $1,650 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,562.57 |
| Consulting Fee | $1,650.00 |
| Education | $116.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $8,174.43 | 2019-2025 | Calquence, Lynparza, Enhertu |
| Lilly USA, LLC | $5,205.62 | 2019-2024 | Retevmo, Jaypirca, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $1,793.20 | 2019-2025 | |
| G1 Therapeutics, INC. | $1,500.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $923.72 | 2019-2025 | |
| Pfizer INC. | $542.58 | 2022-2025 | |
| Daiichi Sankyo INC. | $502.33 | 2020-2025 | Enhertu, Injectafer |
| Merck Sharp & Dohme LLC | $349.11 | 2022-2025 | Keytruda, Welireg, Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $315.76 | 2019-2025 | Fruzaqla, Vpriv, Alunbrig |
| E.R. Squibb & Sons, L.L.C. | $311.63 | 2022-2025 | Opdivo, Opdualag, Krazati |
| Glaxosmithkline, LLC. | $270.88 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Eisai INC. | $263.28 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $243.01 | 2022-2025 | Onivyde, Somatuline Depot, Tazverik |
| Astellas Pharma US INC | $197.93 | 2023-2025 | Xospata, Vyloy, Padcev |
| Incyte Corporation | $196.71 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $185.80 | 2022-2024 | Zoladex, Xermelo |
| Blueprint Medicines Corporation | $145.99 | 2024-2025 | Ayvakit |
| Genentech USA, INC. | $134.78 | 2022-2025 | Polivy, Avastin, Rozlytrek |
| Abbvie INC. | $129.81 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $121.83 | 2019 | |
| Emd Serono, INC. | $119.81 | 2023-2025 | Bavencio |
| Janssen Biotech, INC. | $106.43 | 2019-2025 | Talvey, Darzalex, Tecvayli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.10 | 2019-2025 | |
| Servier Pharmaceuticals LLC | $85.42 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $77.15 | 2020-2025 | |
| Karyopharm Therapeutics INC. | $77.07 | 2023-2025 | Xpovio |
| Deciphera Pharmaceuticals INC. | $74.13 | 2023-2025 | Qinlock, Romvimza |
| Seagen INC. | $71.54 | 2019-2022 | |
| Celgene Corporation | $69.62 | 2019-2025 | Reblozyl, Pomalyst |
| Puma Biotechnology, INC. | $65.45 | 2023-2024 | |
| Gilead Sciences, INC. | $59.11 | 2021-2024 | |
| Cti Biopharma Corp. | $57.10 | 2022-2023 | Vonjo |
| Beone Medicines USA, INC. | $56.70 | 2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $56.67 | 2021-2023 | Libtayo |
| Alnylam Pharmaceuticals INC. | $55.36 | 2022-2024 | Givlaari |
| Blue Earth Diagnostics | $48.92 | 2023-2024 | |
| Mirati Therapeutics, INC. | $46.70 | 2023 | Krazati |
| Kite Pharma, INC. | $45.53 | 2022-2023 | Yescarta |
| Adc Therapeutics America, INC. | $45.39 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $44.80 | 2024-2025 | Monoferric |
| Pharmaessentia USA Corporation | $41.65 | 2024-2025 | Besremi |
| Array Biopharma INC | $36.01 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Aveo Pharmaceuticals, INC. | $32.29 | 2023-2024 | Fotivda |
| Apellis Pharmaceuticals, INC. | $30.64 | 2022-2024 | Empaveli |
| Pharmacyclics LLC, An Abbvie Company | $26.09 | 2022-2023 | Imbruvica |
| Genzyme Corporation | $24.82 | 2025 | |
| Exelixis INC. | $23.38 | 2025 | Cabometyx |
| Adaptive Biotechnologies Corporation | $22.43 | 2022 | |
| Taiho Oncology, INC. | $22.31 | 2022 | |
| Genmab U.S., INC. | $20.76 | 2024 | Epkinly |
| Progenics Pharmaceuticals, INC. | $19.77 | 2024 | |
| Coherus Oncology, INC. | $18.06 | 2023 | |
| Recordati_rare_diseases_inc. | $17.79 | 2023 | Sylvant |
| Rigel Pharmaceuticals, INC. | $17.62 | 2023-2024 | Tavalisse, Rezlidhia |
| Stemline Therapeutics INC. | $16.75 | 2024 | Orserdu |
| Novocure INC. | $15.62 | 2024 | Optune |
| Beigene USA, INC. | $15.47 | 2024 | Brukinsa |
| Sumitomo Pharma America, INC. | $14.46 | 2023 | Orgovyx |
| Agios Pharmaceuticals, INC. | $14.08 | 2025 | Pyrukynd |
| Amgen INC. | $12.90 | 2023 | Blincyto, Kyprolis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elke Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.